Author: admin

Carson Neel Delves into the Essence of Success in Exclusive Online Interview

In an exclusive interview, Carson Neel, ex-footballer and finance expert, shares his views on success. Transitioning smoothly from sports to finance, the SMU student emphasizes quick decision-making, lifelong learning, and ethical finance. He aims to integrate technology and ethics in finance, focusing on broader societal impacts alongside economic growth. Neel defines success as a blend of personal growth, strong relationships, and staying true to values.

In a thought-provoking and exclusive online interview titled “What Does Success Look Like To You? – Carson Neel”, Carson Neel, a former record-breaking football receiver turned finance expert, shares his profound insights on success in both professional and personal realms. This compelling interview, now available online, offers an in-depth exploration of Carson’s unique journey and his forward-thinking approach to finance and leadership.

Carson Neel, a Cedar Park High alum, has transitioned from sports to finance with remarkable fluidity and success. With his recent academic endeavors at SMU’s MSC in Finance program, following a solid foundation at TCU’s Neeley School of Business, Carson brings a unique perspective to the finance industry. His leadership skills, honed as President of the Young Men’s Service League in Cedar Park and an active member of Kappa Sig at TCU, complement his sharp financial acumen. Carson’s passion lies in blending technology with ethics in finance, aiming to drive innovation and positive change in the industry.

In the interview, Carson reflects on the valuable lessons from his football career, particularly the importance of quick decision-making, a skill that he finds indispensable in the fast-paced world of finance. He also discusses the impact of his academic experiences at TCU on his approach to finance, emphasizing the blend of theory and real-world application.

As he pursues his MSC in Finance, Carson expresses his excitement for exploring the intersection of finance and technology, particularly the burgeoning field of fintech. He highlights his commitment to lifelong learning as a means to stay ahead in the dynamic finance sector and stresses the importance of viewing situations from multiple perspectives, a lesson he learned during his time with the Young Men’s Service League.

Looking ahead, Carson envisions bringing a holistic and integrated approach to finance, one that incorporates empathy, ethical considerations, and technological advancements. He aspires to make an impact in the finance industry that goes beyond economic growth, aiming for broader societal contributions.

The interview concludes with Carson’s personal definition of success – a balance of continuous growth, nurturing relationships, and staying true to one’s values. It’s a refreshing take that resonates with professionals across industries.

To read the full interview, click here. 

Media Contact
Contact Person: Carson Neel
Email: Send Email
City: Dallas
State: Texas
Country: United States
Website: https://carsonneel.com/

Twin Cities MN Living Rebrands as The South Metro Realtor, Unveiling a Fresh Identity in the Real Estate Landscape

Lakeville, Minnesota – December 21st, 2023 – Twin Cities MN Living, a prominent Lakeville MN real estate team, is thrilled to announce its rebranding to The South Metro Realtor. This strategic move comes as part of the company’s commitment to better reflect its regional focus and dedication to providing top-notch real estate services in the southern metropolitan area of the Twin Cities.

“We are excited to unveil our new brand as South Metro Realtor. This rebranding reflects our unwavering commitment to delivering exceptional real estate services to the communities and businesses that we have served the most over the last 15 years,” said Chris Mosier, Founder of South Metro Realtor. “Our team is passionate about helping individuals and families find their dream homes and navigate the complexities of real estate transactions, while also having a little fun in the process.  The new name captures the essence of our focus and underscores our dedication to being local experts.  The new brand lets me still stay focused one-on-one for my clients, while having a full team behind me to keep up as we grow.  It also allows me personally to better distinguish who I am and the areas I serve so that I can continue to deliver 5 star service to my clients.”

South Metro Realtor will continue to offer a comprehensive range of real estate services, including buying, selling, and leasing residential and commercial properties. With a team of experienced and dedicated real estate professionals, the company remains committed to providing personalized and client-centric solutions to meet the unique needs of its diverse clientele.

The rebranding is not only a change in name but also an opportunity for South Metro Realtor to refresh its visual identity, including a new logo and updated branding materials. The company’s website and marketing materials have been revamped to reflect the new name and showcase the extensive range of services offered.

Clients, partners, and the community at large can connect with South Metro Realtor through its updated website and its social media channels, where the company will continue to share valuable real estate insights, community news, and property listings.

South Metro Realtor is enthusiastic about this exciting new chapter and looks forward to continuing to serve the real estate needs of the southern metropolitan area with passion, expertise, and a renewed sense of purpose.

About Twin Cities MN Living:

Chris Mosier is a licensed real estate practitioner and has been in the business since 2008. Chris and his family have been living in Lakeville since 1994 and are proud to call it their home. Through the years, Chris has done a lot in the south metro from officiating local soccer games, and earning his Karate Black Belt, to being the Phantom of the Opera in the school musical.  He has helped hundreds of people and their families buy and sell real estate all across the South Metro area.

Chris Mosier has always believed that real estate should be more of a personal relationship between a realtor and a client. Chris believes in servant leadership and education through humor. He knows every single past client by name. 

For more information about Twin Cities MN Living, call 952-412-0643 or visit their website.

Media Contact
Company Name: Christopher Mosier- Bilingual South Metro Realtor
Contact Person: Christopher Mosier
Email: Send Email
Phone: +1 952-412-0643
Address:17305 Cedar Ave #100
City: Lakeville
State: MN 55044
Country: United States
Website: https://www.southmetrorealtor.com/

Ambient, Experimental, and Alternative – Phillip A. Urena Delivers Fusion Single “Tuesday, March 7th, 2023 (Freestyle)”

Ambient, Experimental, and Alternative - Phillip A. Urena Delivers Fusion Single "Tuesday, March 7th, 2023 (Freestyle)"
Phillip Urena’s amalgam of exciting sounds, striking rhythms, and magical tunes makes for a beautiful blend for all to revel in

Phillip A. Urena, a native of Haverstraw, New York, is more than an artist—he is a creator whose music transcends conventional boundaries. A musical polymath, Phillip delves into genres ranging from Hardcore and Hip Hop to Ambient and Rock, creating a fusion that mirrors the eclectic landscape of his influences.

The artist’s newest single – “Tuesday, March 7th, 2023 (Freestyle)” – which dropped on December 6th, is more than just a new single—it’s a collaborative effort infused with personal significance. Sharing the creation with LiL Moon and L’ Royal, the project took shape organically, fueled by creative energy and shared enthusiasm. Originally conceived as LiL Moon’s song, it transformed into a collaborative masterpiece, epitomizing the fluid and interconnected nature of artistic expression.

Phillip’s authenticity is the cornerstone of his musical journey. With a decade-long dedication to mastering the guitar, he brings a wealth of musical knowledge to his compositions. His spirituality plays a pivotal role, acting as a wellspring of inspiration that infuses each note with profound meaning. The positive reception from his inner circle underscores the genuine and relatable nature of his work.

Beyond the confines of a single genre, Phillip embraces the philosophy that “Greatness is a devotional act to the Highest,” a sentiment that guides his artistic endeavors. As he explores new realms of creativity, he invites listeners to join him on a sonic adventure.

Phillip A. Urena’s musical universe extends beyond the auditory realm. A favorite of his, the Red Hot Chili Peppers, has left a lasting imprint on his sonic landscape, contributing to the diverse palette of sounds that define his work. To connect with Phillip’s artistic expressions, one can simply search for his name on various streaming platforms, unlocking a portal to his creative world.

In addition to his musical prowess, Phillip A. Urena has ventured into the world of culinary arts, reflecting his commitment to exploring various avenues of creativity. As he continues to shape his distinctive sound and artistic vision, Phillip remains a dynamic force, inviting audiences to immerse themselves in the authentic and spiritually charged tapestry of his creations.

ABOUT

Embracing a spectrum of genres from Alternative and Ambient to Hardcore and Hip Hop, Phillip A. Urena emerges as a versatile artist with a unique blend of influences. Hailing from Haverstraw, New York, the artist is set to unveil his latest creation—a new single scheduled for release on December 6th. This significant date holds a personal touch, coinciding with his sister’s birthday and featuring the collaborative efforts of LiL Moon and L’ Royal.

In addition to his musical pursuits, Phillip A. Urena has recently delved into the culinary arts, further expanding his creative expression. As he continues to craft music and art that resonates with authenticity, Phillip invites listeners to join him on a journey where creativity and spirituality converge.

LINKS

Spotify: https://open.spotify.com/artist/7pyCURYeHp3WuZHXwQW9Zt?si=nILuG9WaR9acfE6HSI29Ig

Media Contact
Contact Person: Phillip A. Urena
Email: Send Email
Phone: 800-983-1362
City: Haverstraw
State: New York
Country: United States
Website: https://open.spotify.com/artist/7pyCURYeHp3WuZHXwQW9Zt?si=nILuG9WaR9acfE6HSI29Ig

Extensive Stage Small Cell Lung Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

DelveInsight’s, “Extensive Stage Small Cell Lung Cancer Pipeline Insight 2023” report provides comprehensive insights about 40+ Extensive Stage Small Cell Lung Cancer companies and 40+ pipeline drugs in the Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the Extensive Stage Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Extensive Stage Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Extensive Stage Small Cell Lung Cancer Pipeline Report

  • DelveInsight’s Extensive Stage Small Cell Lung Cancer pipeline report depicts a robust space with 40+ Extensive Stage Small Cell Lung Cancer companies working to develop 40+ pipeline therapies for Extensive Stage Small Cell Lung Cancer treatment.
  • The leading Extensive Stage Small Cell Lung Cancer Companies working in the market includes Eli Lilly and Company, Genentech, Bristol-Myers Squibb, Henlix Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., aizhou HoudeAoke Biomedical Co., Ltd., Celgene, MedImmune, Xcovery Holding Company LLC, Lee’s Pharmaceutical Limited, Merck & Co, Astex Pharmaceuticals, and others.
  • Promising Extensive Stages Small Cell Lung Cancer Pipeline Therapies in the various stages of development includes Ifinatamab Deruxtecan (I-DXd), Trilaciclib, Obatoclax, Carboplatin/etoposide, and others.
  • December 2023: Hoffmann-La Roche announced a study of Phase 3 clinical trials for Atezolizumab, Lurbinectedin, Carboplatin and Etoposide. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and atezolizumab treatment in order to be considered for eligibility screening for the maintenance phase. Eligible participants will be randomized in a 1:1 ratio to receive either lurbinectedin plus atezolizumab or atezolizumab in the maintenance phase.
  • December 2023: Shanghai Henlius Biotech announced a study of Phase 3 clinical trials for Serplulimab + chemotherapy (carboplatin-etoposide) and Atezolizumab + chemotherapy (carboplatin-etoposide). A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE).
  • December 2023: Amgen announced a study of Phase 1 clinical trials for Tarlatamab, Carboplatin, Etoposide, Durvalumab and Atezolizumab. This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.

 

Request a sample and discover the recent advances in Extensive Stage Small Cell Lung Cancer Treatment Drugs @ Extensive Stage Small Cell Lung Cancer Pipeline Outlook Report

 

The Extensive Stage Small Cell Lung Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Extensive Stage Small Cell Lung Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Extensive Stage Small Cell Lung Cancer clinical trial landscape.

 

Extensive Stage Small Cell Lung Cancer Overview

Extensive Stage Small Cell Lung Cancer (ESCLC) (ESCLC) is in the stage where it has spread to other parts of the body, such as the other lung or the brain. Without treatment, the average life expectancy for a person with an extensive-stage small cell lung cancer diagnosis is two to four months.

 

Find out more about Extensive Stage Small Cell Lung Cancer Treatment Landscape @ Drugs for Extensive Stage Small Cell Lung Cancer Treatment

 

Extensive Stage Small Cell Lung Cancer Emerging Drugs Profile

  • LY 2510924: Eli Lilly and Company
  • Tiragolumab: Genentech

 

Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 40+ key Extensive Stage Small Cell Lung Cancer companies which are developing the Extensive Stage Small Cell Lung Cancer therapies. The Extensive Stage Small Cell Lung Cancer companies which have their Extensive Stage Small Cell Lung Cancer (ESCLC) drug candidates in the most advanced stage, i.e. phase III include, Genentech.

 

DelveInsight’s Extensive Stage Small Cell Lung Cancer Pipeline Report covers around 40+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

 

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Learn more about the emerging Extensive Stage Small Cell Lung Cancer Pipeline Therapies @ Extensive Stage Small Cell Lung Cancer Clinical Trials Assessment

 

Scope of the Extensive Stage Small Cell Lung Cancer Pipeline Report

  • Coverage- Global
  • Extensive Stage Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Extensive Stage Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Extensive Stage Small Cell Lung Cancer Companies- Eli Lilly and Company, Genentech, Bristol-Myers Squibb, Henlix Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., aizhou HoudeAoke Biomedical Co., Ltd., Celgene, MedImmune, Xcovery Holding Company LLC, Lee’s Pharmaceutical Limited, Merck & Co, Astex Pharmaceuticals, and others.
  • Extensive Stages Small Cell Lung Cancer Pipeline Therapies- Ifinatamab Deruxtecan (I-DXd), Trilaciclib, Obatoclax, Carboplatin/etoposide, and others.

 

Dive deep into rich insights for new drugs for Extensive Stage Small Cell Lung Cancer Treatment, Visit @ Extensive Stage Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Extensive Stage Small Cell Lung Cancer Executive Summary
  3. Extensive Stage Small Cell Lung Cancer Overview
  4. Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics
  5. Extensive Stage Small Cell Lung Cancer Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Tiragolumab: Genentech
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. LY 2510924: Eli Lilly and Company
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. SYHA 1807: CSPC ZhongQi Pharmaceutical Technology
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Extensive Stage Small Cell Lung Cancer Companies
  17. Extensive Stage Small Cell Lung Cancer Key Products
  18. Extensive Stage Small Cell Lung Cancer Unmet Needs
  19. Extensive Stage Small Cell Lung Cancer Market Drivers and Barriers
  20. Extensive Stage Small Cell Lung Cancer Future Perspectives and Conclusion
  21. Extensive Stage Small Cell Lung Cancer Analyst Views
  22. Extensive Stage Small Cell Lung Cancer Key Companies
  23. Appendix

 

For further information on the Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics, reach out to Extensive Stage Small Cell Lung Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Extensive Stage Small Cell Lung Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

Centellian24: Discover Centella asiatica and Bring the Best of K-Beauty Skincare and Facial Devices Home for Christmas

A pioneering derma-cosmetic brand powered by Dongkook Pharmaceutical’s over fifty years of skin science technology shares its latest skincare innovations on Amazon as perfect gift options for this Christmas. The lineup includes the advanced Madeca Cream Season 6, true best-seller of the brand, and the Madeca Prime Facial Toning Device, a versatile 3-in-1 microcurrent device.

In the spirit of the festive season, Centellian24, renowned for its derma-cosmetic expertise, has unveiled an array of skin care products made with Centella Asiatica Extract and a state-of-the-art facial device on Amazon, making them the ideal Christmas gifts for beauty enthusiasts.

Centellian24 embodies innovative skincare from South Korea. This moisturizing cream with centella asiatica, Madeca Cream Season 6, is a testimony to Korean skincare excellence. Infused with TECA (titrated extract of Centella Asiatica) and fermented Centella Asiatica extract, the cream is expertly formulated to stimulate collagen production and repair damaged skin. The advanced TECA encapsulated formula ensures deep absorption of active ingredients, offering intense moisturization and improved skin elasticity. 

This cream is a quintessential product for those seeking to diminish fine lines and signs of aging, making it an ideal gift for Christmas. Its unique hyaluronic acid, collagen, and elastin blend caters to sensitized, dry, sagging, and dull skin, promoting an even skin tone, radiance, and clarity. The cream boasts exceptional absorption and comfort, providing efficient hydration without a greasy feel.

In addition to its skincare line, the brand introduces the Madeca Prime Facial Toning Device. This innovative 3-in-1 microcurrent device sets itself apart in the beauty device market with three distinct modes, each serving a different purpose. Unlike traditional galvanic devices limited to ionized cosmetics, the Madeca Prime works with a broader range of skincare products, offering versatility and enhanced results. The device can be paired with three different ampoules by Centellian24, each formulated to maximize the device’s effectiveness, ensuring the best results.

Behind Centellian24’s success is Dongkook Pharmaceutical, a South Korean healthcare group with a prestigious history spanning over five decades. Dongkook’s expertise in Centella Asiatica has led to breakthroughs like Madecassol, a household name in Korea. Now, Dongkook leverages this expertise to offer innovative skincare solutions through Centellian24.

Centellian24 offers special promotions on Amazon to celebrate the holiday season, providing an excellent opportunity to purchase these innovative skincare and beauty device products at attractive prices. This Christmas, give the gift of beauty and wellness with Centellian24’s outstanding range of products.

Media Contact
Company Name: Centellian24
Contact Person: Forsit
Email: Send Email
Country: United States
Website: https://amzn.to/49Ag8jH

Ryan Nicholas Marks a Decade Milestone with The DamonSellsHomes Team

Fairfax, Virginia – December 21, 2023 – The DamonSellsHomes Team, the #1 Team for Coldwell Banker in the state of Virginia for 5 years running, is delighted to celebrate a significant milestone with one of its esteemed members, Ryan Nicholas, as he commemorates 10 years of dedicated service with the team.

Since joining The DamonSellsHomes Team a decade ago, Ryan Nicholas has consistently demonstrated a commitment to excellence, a passion for client satisfaction, and a deep understanding of the intricacies of the real estate industry. His journey with the team has been marked by numerous success stories, demonstrating his prowess in navigating the ever-evolving real estate landscape.

Ryan’s unique blend of professionalism, market knowledge, and genuine care for his clients has contributed significantly to The DamonSellsHomes Team’s success and reputation. Over the years, he has played a pivotal role in helping individuals and families find their dream homes, and sell their old homes, making both the home-buying and home-selling process a seamless and enjoyable experience.

“I am honored to have been a part of The DamonSellsHomes Team for the past 10 years,” said Ryan Nicholas. “It has been an incredible journey, and I am grateful for the trust and confidence that both my clients and the team have placed in me. In my next 10 years I pledge my ongoing commitment to providing the highest level of service and expertise to my clients.”

The DamonSellsHomes Team recognizes Ryan’s dedication and achievements by celebrating this milestone with a special event this month. The team and its clients look forward to many more years of success with Ryan as an integral member.

About The DamonSellsHomes Team:

The DamonSellsHomes Team is a popular and reliable real estate agency in Fairfax, Virginia. Over the years, the team has helped a lot of home buyers, sellers, and investors achieve their respective goals. It is currently made up of the following members.

Damon Nicholas – Senior Executive Team Leader

Damon entered the real estate field initially in 1985 as a part-time buyer’s agent, to share some of his wife Debbie’s workload from her growing real estate business. He dedicated himself full-time to real estate in 1990. Damon certainly found his niche in the real estate world, consistently receiving the highest honors from Coldwell Banker and the Northern Virginia Association of Realtors (NVAR). He is honored to be one of the top Realtors® in the USA by RealTRENDS and most recently Damon Nicholas & The DamonSellsHomes Team were named #1 Realtor® in Virginia for Coldwell Banker Residential Brokerage. Damon’s continued success lies in his and his team’s special ability to thoroughly represent buyers and sellers in all price ranges, whether their need is a $300,000 or a $3,000,000 home.

Barbara Blumer – Senior Executive Team Realtor

Barbara has been with The DamonSellsHomes Team since May 2004, and has sold over 300 homes since joining the team. As Senior Executive Team Realtor, as well as being an Accredited Staging Professional, Barbara shares with her clients the very best proven ways to prepare a home with low-cost updates and manageable design plans to create immediate buyer interest, leading to the highest sales price possible for her clients.

Debbie Nicholas – Senior Executive Team Realtor

Debbie’s extensive experience as a Virginia Real Estate Broker, with top honors as a Northern Virginia Association of Realtors Top Producer for residential real estate, has prepared her to be a valuable resource to her clients and team Realtors®, too. She has been honored as a MAME award recipient for excellence in New Home Sales Marketing and as a record-breaker for serving incoming and out-going relocation clients. Featured numerous times on local news during the Clifton custom homes explosion, Debbie continues to serve Northern Virginia homeowners with the same professional distinction she established years ago. She creates business systems for team development, personal marketing, and most importantly: reliable and capable client service. Debbie’s got the pedigree and understanding to provide the personalized service you deserve.

Ryan Nicholas – Senior Team Realtor

Ryan’s top priorities include pursuing the outcome that serves his clients’ best interests. As a millennial himself, Ryan loves helping first-time home-buyers find their first home. With the rapid experience he has gained working on one of the most dominant teams in Northern Virginia, he is also well-equipped to serve any client need. His experience includes short sales, first-time home buyers, young families moving up, boomers moving to urban settings, and luxury living.

Josie Barondess – Senior Team Realtor

Josie serves both her clients and the team as Senior Team Realtor®, Accredited Staging Professional and as Team Listing Coordinator. Because potential buyers get their first look at a home online, Josie utilizes her incredible skills to assist with staging, then coordinating professional photography and copy-writing to enhance each listing to its full potential. Josie then creates a brochure unique to each listing, highlighting not only the property but the surrounding neighborhood so that potential buyers unfamiliar with the area have this vital initial information to make their best decision. She has also been a member of the Million Dollar Sales Club.

Steve Fred – Executive Team Realtor

With Steve’s background, it should come as no surprise that he is certified as a Military Relocation Professional. Steve credits his former Air Force boss in Nebraska, who retired and became the Realtor® who sold Steve’s first home for him, with the inspiration for his career in real estate. He began selling real estate in 2000 and earned NVAR Multi-Million Dollar Club status multiple times, specializing in the Fairfax County areas of Fairfax, Annandale, Alexandria and Arlington.

Haley McBryan – Team Realtor Associate

Haley is passionate about finding clients their perfect space, where they feel the most comfortable. For her, finding the clients’ homes is all about the clients and their wants and needs. Whatever the client’s life looks like, Haley wants to make sure their home fits those needs. Along with her real estate license Haley also studied interior design and have a background in construction.

For more information about The DamonSellsHomes Team call 703.935.5699 or visit their website.

Media Contact
Company Name: The DamonSellsHomes Team
Contact Person: Damon Nicholas
Email: Send Email
Phone: +1 703-502-8787
Address:Coldwell Banker Realty, 4000 Legato Rd #100
City: Fairfax
State: VA 22033
Country: United States
Website: https://damonsellshomes.com/

Meet ‘Female Family Conflict Resolutions to Communicate Course, Subtitle: Unconfined Revelations, Prequel’, the New eBook Course Bringing Families, Friends, and Co-Workers Closer Ahead of the Holidays

This new eBook course offers a blueprint for interpersonal relationships among women, with tips on parenting and distinguishes family responsibilities and roles of siblings, grandparents, in-laws, aunts, cousins, adult children, nieces, nephews, friendships, and social navigation techniques to overcome gaslighting, estrangement, dysfunctional behaviors, unjust isolation, and establishing mental health strategies, and more

One new eBook course, ‘FEMALE FAMILY CONFLICT RESOLUTIONS TO COMMUNICATE COURSE, SUBTITLE: Unconfined Revelations, Prequel’, is revolutionizing interpersonal relationships between women.

 Women and men communicate very differently, with women being more sensitive to interpersonal symbolism in conversational settings than men. This can lead to conflict in various areas in terms of gaslighting, family dysfunction, estrangement, mental health, and more. In ‘FEMALE FAMILY CONFLICT RESOLUTIONS TO COMMUNICATE COURSE, SUBTITLE: Unconfined Revelations, Prequel ’, author Brandei S. Penwrite presents her experiences for directing change when roles of family members and differences become nuances of relationships arise. 

Readers will learn how to identify common sources of family conflict among women; apply effective communication technique to resolve conflict; establish healthy boundaries; improve communications during family gatherings and special occasions; acknowledge, with respect, and accept others personal rights and limitation; and more. Families and groups can sit down together and complete the entire course in approximately four hours, making it an ideal activity for family members, friends, and co- workers ahead of the Christmas holidays and New Year’s resolutions.

Participants work through eleven modules covering mothers and daughters; fathers, sisters; female relatives; sisters and brothers; female covet; married versus single women; husband/wife conflict; off-limit topics, and individual limitations; healthy collaborations with loved ones; and more. Each module carries participants through foundational layers to understand the basics of each role, through critical thinking and applying learned exercises to make relationships flow with enriched happiness.

“Family is a cornerstone of our lives,” said Penwrite. “Varied differences in each member’s personality, expectations, and the distinguished duty of each relative’s role can negatively poison the entire family unit. With engagements of various women this can give rise to quarrels and misinterpretations. Negative habits can take a toll on emotional well-being and overall family togetherness, spreading cancer-like poison to future generations. But there is hope.”

According to Penwrite, the eBook course is dedicated to her heavenly rested and cherished parents, brother, and late sister. The last lost changed her mindset to lovingly impact unjust isolation family interactions, despite bias and disagreements.

Ahead of the holidays, people everywhere can give the gift of healthy, happy relationships with ‘FEMALE FAMILY CONFLICT RESOLUTIONS TO COMMUNICATE COURSE, SUBTITLE: Unconfined Revelations, Prequel’. More information can be found at https://second2nonelife.com

ABOUT BRANDEI S. PENWRITE

Most High God’s daughter, a classy, intelligent, and resilient oldest daughter. Pragmatic, resourceful, inspiring, sassy, yet a forward-thinker whose frugality afforded her to persevere and compete, with a nurturing, thoughtful, and assertive spirit. She embraces her love of spoken word, live music, nature, art, karaoke, cultural events, and traveling.  

Brandei is a Business Consultant, gifted to discover God-given critical skills for entrepreneurship. She retired from Corporate America, after decades of learned lessons, thereof, she was led to pursue a certification in Reiki, to empower universal healing.

Brandei’s second eBook is titled, ‘MANIFESTED REVELATIONS, Subtitle: Empowered Overcomer’, a memoir is scheduled to release 1/15/24. Amazon pre-orders are soon available at https://amazon.com/dp/B0CQ5G5TXX.

Media Contact
Contact Person: Brandei S. Penwrite
Email: Send Email
Country: United States
Website: https://second2nonelife.com

Ewing Sarcoma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)

DelveInsight’s, “Ewing Sarcoma Pipeline Insights 2023” report provides comprehensive insights about 25+ Ewing Sarcoma companies and 25+ pipeline drugs in the Ewing Sarcoma pipeline landscape. It covers the Ewing Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ewing Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Ewing Sarcoma Pipeline Report

  • DelveInsight’s Ewing Sarcoma pipeline report depicts a robust space with 25+ Ewing Sarcoma companies working to develop 25+ pipeline therapies for Ewing Sarcoma treatment.
  • The leading Ewing Sarcoma Companies working in the market include Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals, Oncternal Therapeutics, Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and others.
  • Promising Ewing Sarcoma Pipeline Therapies in the various stages of development includes Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), TB-403 20mg/kg, Irinotecan, Temozolomide, exatecan mesylate, CP-751,871, plerixafor, and others.
  • December 2023: St. Jude Children’s Research Hospital announced a study of Phase 1 & 2 clinical trials for Onivyde, Talazoparib and Temozolomide. The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be randomly assigned to either Arm A or Arm B. The purpose of the phase I study is to determine the highest tolerable doses of the combinations of treatment given in each Arm.
  • December 2023: Children’s Hospital of Philadelphia announced a study of Phase 1 clinical trials for Cabozantinib. The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory Ewing sarcoma and osteosarcoma.
  • December 2023: Fusion Pharmaceuticals Inc. announced a study of Phase 1 clinical trials for [225]-FPI-2059 and [111In]-FPI-2058. This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours.

 

Request a sample and discover the recent advances in Ewing Sarcoma Treatment Drugs @ Ewing Sarcoma Pipeline Outlook Report

 

The Ewing Sarcoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Ewing Sarcoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Ewing Sarcoma clinical trial landscape.

 

Ewing Sarcoma Overview

Ewing sarcoma is the second most common primary malignant bone tumor, mostly affecting adolescents in the second decade of their life, and it is a highly metastatic class of sarcoma. Despite the use of radiotherapy or surgery, historically, an estimated 85% to 90% of patients died within a few months from a metastasis.

 

Find out more about Ewing Sarcoma Treatment Landscape @ Drugs for Ewing Sarcoma Treatment

 

Ewing Sarcoma Emerging Drugs Profile

  • Vigil: Gradalis
  • ONCT216: Oncternal Therapeutics
  • SP-2577: Salarius Pharmaceuticals

 

Ewing Sarcoma Pipeline Therapeutics Assessment

There are approx. 25+ Ewing Sarcoma companies which are developing the Ewing Sarcoma therapies. The Ewing Sarcoma companies which have their Ewing Sarcoma drug candidates in the most advanced stage, i.e. Phase III include, Gradalis.

 

DelveInsight’s Ewing Sarcoma pipeline report covers around 25+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Ewing Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Ewing Sarcoma Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Learn more about the emerging Ewing Sarcoma Pipeline Therapies @ Ewing Sarcoma Clinical Trials Assessment

 

Scope of the Ewing Sarcoma Pipeline Report

  • Coverage- Global
  • Ewing Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Ewing Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Ewing Sarcoma Companies- Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals, Oncternal Therapeutics, Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and others.
  • Ewing Sarcoma Pipeline Therapies- Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), TB-403 20mg/kg, Irinotecan, Temozolomide, exatecan mesylate, CP-751,871, plerixafor, and others.

 

Dive deep into rich insights for new drugs for Ewing Sarcoma treatment, Visit @ Ewing Sarcoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Ewing Sarcoma Executive Summary
  3. Ewing Sarcoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Ewing Sarcoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Vigil: Gradalis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. ONCT216: Oncternal Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. SP-2577: Salarius Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. CLR 131: Cellectar Biosciences
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Ewing Sarcoma Companies
  21. Ewing Sarcoma Key Products
  22. Ewing Sarcoma Unmet Needs
  23. Ewing Sarcoma Market Drivers and Barriers
  24. Ewing Sarcoma Future Perspectives and Conclusion
  25. Ewing Sarcoma Analyst Views
  26. Ewing Sarcoma Key Companies
  27. Appendix

 

For further information on the Ewing Sarcoma pipeline therapeutics, reach out to Ewing Sarcoma Unmet Needs and Analyst Views

 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ewing Sarcoma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)

Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)

DelveInsight’s, “Diffuse Intrinsic Pontine Glioma Pipeline Insight 2023” report provides comprehensive insights about 25+ Diffuse Intrinsic Pontine Glioma companies and 25+ pipeline drugs in the Diffuse Intrinsic Pontine Glioma pipeline landscape. It covers the Diffuse Intrinsic Pontine Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Intrinsic Pontine Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Diffuse Intrinsic Pontine Glioma Pipeline Report

  • DelveInsight’s Diffuse Intrinsic Pontine Glioma pipeline report depicts a robust space with 25+ Diffuse Intrinsic Pontine Glioma companies working to develop 25+ pipeline therapies for Diffuse Intrinsic Pontine Glioma treatment.
  • The leading Diffuse Intrinsic Pontine Glioma Companies working in the market include Midatech, Kazia Therapeutics, Kintara Therapeutics, Oncotelic Therapeutics, Antisense Pharma, Y-mAbs Therapeutics, PTC Therapeutics, Celgene Corporation, and others.
  • Promising Diffuse Intrinsic Pontine Glioma Pipeline Therapies in the various stages of development includes BXQ-350, ONC201, PTC596, Radiotherapy, AloCELYVIR, Temozolomide, Bevacizumab, Irinotecan, and others.
  • December 2023: Luca Szalontay announced a study of Phase 1 clinical trials for Infusate with MTX110 and gadolinium. The purpose of this Phase I study is to find the maximum tolerated dose of MTX110 (a water-soluble Panobinostat nanoparticle formulation) and Gadolinium that can be given safely in children with newly diagnosed diffuse midline gliomas. All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered with a pump directly into the tumor over 9-11 days.
  • December 2023: Sabine Mueller, MD, PhD announced a study of Phase 1 & 2 clinical trials for Nivolumab and K27M peptide. This study will assess the safety and immune activity of a synthetic peptide vaccine specific for the H3.3.K27M epitope given in combination with poly-ICLC and the H3.3.K27M epitope given in combination with poly-ICLC and the PD-1 inhibitor, nivolumab, in HLA-A2 (02:01)+ children with newly diagnosed DIPG or other midline gliomas that are positive for H3.3K27M.
  • December 2023: Y-mAbs Therapeutics announced a study of Phase 1 clinical trials for Radioactive iodine-labeled monoclonal antibody omburtamab. In this study, the researchers want to find out how safe 124I-omburtamab given by CED is at different dose levels. They will look to see what effects (both good and bad) it has on the patient. The dose of 124I-omburtamab will increase for each new group of patients. The procedure has already been safely performed with lower doses and infusion volumes in a number of patients here at MSKCC. The amount they get will depend on when they enter the study.

 

Request a sample and discover the recent advances in Diffuse Intrinsic Pontine Glioma Treatment Drugs @ Diffuse Intrinsic Pontine Glioma Pipeline Outlook Report

 

The Diffuse Intrinsic Pontine Glioma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Diffuse Intrinsic Pontine Glioma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Diffuse Intrinsic Pontine Glioma clinical trial landscape.

 

Diffuse Intrinsic Pontine Glioma Overview

Diffuse intrinsic pontine gliomas (DIPGs) are highly-aggressive and difficult-to-treat brain tumors found at the base of the brain. They are glial tumors, meaning they arise from the brain’s glial tissue — tissue made up of cells that help support and protect the brain’s neurons. These tumors are found in an area of the brainstem called the pons, which controls many of the body’s most vital functions such as breathing, blood pressure and heart rate.

 

Find out more about Diffuse Intrinsic Pontine Glioma Treatment Landscape @ Drugs for Diffuse Intrinsic Pontine Glioma Treatment

 

Diffuse Intrinsic Pontine Glioma Emerging Drugs Profile

  • MTX 110: Midatech
  • Paxalisib: Kazia Therapeutics

 

Diffuse Intrinsic Pontine Glioma Pipeline Therapeutics Assessment

There are approx. 25+ Diffuse Intrinsic Pontine Glioma companies that are developing the Diffuse Intrinsic Pontine Glioma therapies. The Diffuse Intrinsic Pontine Glioma companies that have their Diffuse Intrinsic Pontine Glioma drug candidates in the most advanced stage, i.e. phase I/II include, Midatech.

 

DelveInsight’s Diffuse Intrinsic Pontine Glioma pipeline report covers around 25+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued and inactive candidates

 

Diffuse Intrinsic Pontine Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Diffuse Intrinsic Pontine Glioma Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Learn more about the emerging Diffuse Intrinsic Pontine Glioma Pipeline Therapies @ Diffuse Intrinsic Pontine Glioma Clinical Trials Assessment

 

Scope of the Diffuse Intrinsic Pontine Glioma Pipeline Report

  • Coverage- Global
  • Diffuse Intrinsic Pontine Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Diffuse Intrinsic Pontine Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Diffuse Intrinsic Pontine Glioma Companies- Midatech, Kazia Therapeutics, Kintara Therapeutics, Oncotelic Therapeutics, Antisense Pharma, Y-mAbs Therapeutics, PTC Therapeutics, Celgene Corporation, and others.
  • Diffuse Intrinsic Pontine Glioma Pipeline Therapies- BXQ-350, ONC201, PTC596, Radiotherapy, AloCELYVIR, Temozolomide, Bevacizumab, Irinotecan, and others.

 

Dive deep into rich insights for new drugs for Diffuse Intrinsic Pontine Glioma treatment, Visit @ Diffuse Intrinsic Pontine Glioma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Diffuse Intrinsic Pontine Glioma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Diffuse Intrinsic Pontine Glioma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase I/II)
  11. MTX 110: Midatech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name : Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Diffuse Intrinsic Pontine Glioma Key Companies
  21. Diffuse Intrinsic Pontine Glioma Key Products
  22. Diffuse Intrinsic Pontine Glioma Unmet Needs
  23. Diffuse Intrinsic Pontine Glioma Market Drivers and Barriers
  24. Diffuse Intrinsic Pontine Glioma Future Perspectives and Conclusion
  25. Diffuse Intrinsic Pontine Glioma Analyst Views
  26. Diffuse Intrinsic Pontine Glioma Key Companies
  27. Appendix

 

For further information on the Diffuse Intrinsic Pontine Glioma pipeline therapeutics, reach out to Diffuse Intrinsic Pontine Glioma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)

Alex Afandi Featured in Exclusive Online Interview

Alex Afandi, a California-based entrepreneur, shares his life journey in an online interview, “Alex Afandi: A Journey of Faith, Family, and Entrepreneurial Success.” He discusses transitioning from Verizon to the medical diagnostics field and becoming an entrepreneur. A family man and devoted to his faith, Afandi emphasizes resilience, adaptability, and balancing professional and personal life.

Alex Afandi, a renowned California-based entrepreneur and investor, has been featured in an insightful online interview titled “Alex Afandi: A Journey of Faith, Family, and Entrepreneurial Success.” The interview delves into Afandi’s multifaceted life, showcasing his journey from a business development role at Verizon to becoming a significant figure in the Medical Diagnostics field, and eventually, a successful entrepreneur and investor.

In the interview, Afandi shares his experiences and insights, highlighting his commitment as a family man and his dedication to his faith, which have been central to his life. The discussion covers various aspects of his career, his personal interests, and his philosophies on success and setbacks. Afandi’s journey is a testament to the power of resilience, adaptability, and the importance of balancing professional ambition with personal values.

Key Highlights from the Interview:

Background and Career Evolution: Afandi talks about his educational background in Business Administration and his evolution from Verizon to the medical diagnostics field, leading to his current focus on acquiring and nurturing small businesses.

Personal Life and Interests: A dedicated family man and man of God, Afandi shares his deep commitment to his family and elderly parents. He discusses his passions outside of work, including cooking, pickleball, hiking, and his volunteer work.

Philosophy on Success: Afandi’s philosophy emphasizes that success involves progressively realizing one’s goals and learning from setbacks, viewing them as opportunities for growth.

Afandi’s story is not just about professional achievements; it’s about overcoming challenges, embracing life’s lessons, and maintaining a harmonious balance between work and personal life. His experiences and insights are an inspiration to many, demonstrating how one can navigate the complexities of life with faith, determination, and a commitment to values.

To read the full interview, click here.

Media Contact
Contact Person: Alex Afandi
Email: Send Email
State: California
Country: United States
Website: https://www.alexafandi.com/